10x Genomics (TXG) Receivables - Net (2018 - 2026)

10x Genomics has disclosed Receivables - Net across 9 years of filings, most recently posting $39.0 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $39.0 million, down 25.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.0 million (down 25.72% YoY), and the FY2025 annual result was $47.0 million, down 46.49% from the prior year.
• Receivables - Net came in at $39.0 million for Q1 2026 at 10x Genomics, down from $47.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $114.8 million in Q4 2023 to a low of $39.0 million in Q1 2026.
• The 5-year median for Receivables - Net is $83.5 million (2024), against an average of $77.1 million.
• Across the five-year window, Receivables - Net surged 33.3% in 2022 and tumbled 47.59% in 2025, its largest moves.
• 10x Genomics' Receivables - Net stood at $104.2 million in 2022, then increased by 10.19% to $114.8 million in 2023, then declined by 23.49% to $87.9 million in 2024, then sank by 46.49% to $47.0 million in 2025, then fell by 16.98% to $39.0 million in 2026.
• The last three Receivables - Net figures came in at $39.0 million (Q1 2026), $47.0 million (Q4 2025), and $43.8 million (Q3 2025), per Business Quant data.